Jefferies’s $36 target on PCRX

PCRX Pacira Biosciences Inc

$36.4 → $36 (-1%) by Oct 2027

Hold · maintains · said Oct 8, 2026 · 12-month default horizon

Open: judged on the close on Oct 8, 2027

The article this target came from

Jefferies downgrades Pacira Pharmaceuticals stock rating on Viatris deal

Investing.com · Oct 8, 2026

Jefferies downgraded Pacira Pharmaceuticals (NASDAQ:PCRX) to Hold from Buy and set a price target of $36.00.

Jefferies’s track record → Pacira Biosciences Inc →

A fact about what Jefferies published, as reported by Investing.com, not a recommendation from Dalsna Finance; Jefferies is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.